Monitoring Tumor Response after Liposomal Doxorubicin in Combination with Liposomal Vinorelbine Treatment Using 3′-Deoxy-3′-[18F]Fluorothymidine PET

Wu, Chun Yi; Tang, Jo Hsin; Chan, Pei Chia; Li, Jia Je; Lin, Ming Hsien; Shen, Chih Chieh; Liu, Ru‐Shi; Wang, Hsin Ell

doi:10.1007/s11307-016-1005-2

Cited by 3 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…52 Mn-labeled Doxil ® revealed the long circulation and distributions in organs by PET-CT (Figures 15A,G) (Gawne et al, 2018) as well as 64 Cu-liposome (Lee et al, 2018). Similarly, SPECT-CT also offered the information on distributions of liposomal doxorubicin and liposomal vinorelbine, and validated the absence of competing effect (Wu et al, 2017). 188 Re-labeled nanoliposomes visualized the treatment of doxorubicin in human colorectal adenocarcinomabearing mice by SPECT-CT (Chen et al, 2010).…”

Section: Chemotherapy With Chemodynamic Therapy (Cdt) and Starvation ...mentioning

confidence: 91%

Liposomes as Multifunctional Nano-Carriers for Medicinal Natural Products

et al. 2022

View full text Add to dashboard Cite

Although medicinal natural products and their derivatives have shown promising effects in disease therapies, they usually suffer the drawbacks in low solubility and stability in the physiological environment, low delivery efficiency, side effects due to multi-targeting, and low site-specific distribution in the lesion. In this review, targeted delivery was well-guided by liposomal formulation in the aspects of preparation of functional liposomes, liposomal medicinal natural products, combined therapies, and image-guided therapy. This review is believed to provide useful guidance to enhance the targeted therapy of medicinal natural products and their derivatives.

show abstract

Section: Chemotherapy With Chemodynamic Therapy (Cdt) and Starvation ...mentioning

confidence: 91%

Liposomes as Multifunctional Nano-Carriers for Medicinal Natural Products

et al. 2022

View full text Add to dashboard Cite

show abstract

“…At 48 h postincubation, the viability of the cells was determined by the 2,5-diphenyl-2 H -tetrazolium bromide (MTT) assay as previously reported. 21 Briefly, the medium was replaced by the MTT solution (500 μL) and then kept at 37 °C for 3 h. After incubation, the MTT solution was removed and dimethyl sulfoxide solution (1 mL) was added to dissolve the formed crystals. The absorbance at 570 nm was recorded by an ELISA reader (TECAN Trading AG, Mannedorf, Switzerland).…”

Section: Methodsmentioning

confidence: 99%

“…Various concentrations of 177 Lu-labeled 11A IgG, J591 IgG, or PSMA-617 were added to the culture medium. At 48 h postincubation, the viability of the cells was determined by the 2,5-diphenyl-2 H -tetrazolium bromide (MTT) assay as previously reported . Briefly, the medium was replaced by the MTT solution (500 μL) and then kept at 37 °C for 3 h. After incubation, the MTT solution was removed and dimethyl sulfoxide solution (1 mL) was added to dissolve the formed crystals.…”

Section: Methodsmentioning

confidence: 99%

Tumor-Targeting Ability of Novel Anti-Prostate-Specific Membrane Antigen Antibodies

et al. 2022

Self Cite

View full text Add to dashboard Cite

Patients with prostate-specific membrane antigen (PSMA)-positive tumors can benefit from PSMA-targeted therapy; thus, we have constructed a phage-displayed synthetic antibody library for the production of novel PSMA antibodies with superior PSMA-targeting ability, favoring clinical management. The binding affinities of anti-PSMA antibodies were verified by an enzyme-linked immunosorbent assay (ELISA). Several in vitro and in vivo experiments, including cellular uptake, internalization, and cytotoxicity studies, micro single photon emission computed tomography (microSPECT)/CT, and biodistribution studies, were performed to select the most promising antibody among six different antibodies. The results showed the target affinities of our antibodies in the ELISA assays (7A, 8C, 8E, and 11A) were comparable to the existing antibodies (J591). The half-maximal effective concentrations of 7A, 8C, 8E, 11A, and J591 were 2.95, 6.64, 5.50, 2.08, and 4.79, respectively. The radiochemical yield of 111 In-labeled antibodies ranged from 30% to 50% with high radiochemical purity (>90%). In the cellular uptake studies, the accumulated radioactivity of 111 In-J591, 111 In-7A, and 111 In-11A increased over time. The internalized percentage of 111 In-11A was the highest (32.14% ± 2.06%) at 48 h after incubation, whereas that of 111 In-J591 peaked at 22.43% ± 4.38% at 24 h and dropped to 13.52% ± 3.03% at 48 h postincubation. Twenty-four hours after injection, radioactivity accumulation appeared in the LNCaP xenografts of the mice injected with 111 In-11A, 111 In-8E, 111 In-7A, and 111 In-J591 but not in the xenografts of the 111 In-8C-injected group. Marked liver uptake was noticed in all groups except the 111 In-11A-injected group. Moreover, the killing effect of 177 Lu-11A was superior to that of 177 Lu-J591 at low concentrations. In conclusion, we successfully demonstrated that 11A IgG owned the most optimal biological characteristics among several new anti-PSMA antibodies and it can be an excellent PSMA-targeting component for the clinical use.

show abstract

“…Another key component is doxorubicin, which could inhibit the biosynthesis of DNA, a routinely used common chemotherapy drug. 26 Numerous clinical studies have combined vinorelbine with doxorubicin [27][28][29][30] for breast cancer therapy. However, the survival rate for free vinorelbine and doxorubicin or doxorubicin alone in metastatic breast cancer were low 31 owing to low penetration and limited distribution of agents in the tumor site.…”

Section: Introductionmentioning

confidence: 99%

Fibronectin-targeted dual-acting micelles for combination therapy of metastatic breast cancer

Gong

Chen

Ren

et al. 2020

Sig Transduct Target Ther

View full text Add to dashboard Cite

Stage IV breast cancer, which has a high risk of invasion, often develops into metastases in distant organs, especially in the lung, and this could threaten the lives of women. Thus, the development of more advanced therapeutics that can efficiently target metastatic foci is crucial. In this study, we built an dual-acting therapeutic strategy using micelles with high stability functionalized with fibronectin-targeting CREKA peptides encapsulating two slightly soluble chemotherapy agents in water, doxorubicin (D) and vinorelbine (V), which we termed C-DVM. We found that small C-DVM micelles could efficiently codeliver drugs into 4T1 cells and disrupt microtubule structures. C-DVM also exhibited a powerful ability to eradicate and inhibit invasion of 4T1 cells. Moreover, an in vivo pharmacokinetics study showed that C-DVM increased the drug circulation half-life and led to increased enrichment of drugs in lung metastatic foci after 24 h. Moreover, dual-acting C-DVM treatment led to 90% inhibition of metastatic foci development and reduced invasion of metastases. C-DVM could potentially be used as a targeted treatment for metastasis and represents a new approach with higher therapeutic efficacy than conventional chemotherapy for stage IV breast cancer that could be used in the future.

show abstract

Monitoring Tumor Response after Liposomal Doxorubicin in Combination with Liposomal Vinorelbine Treatment Using 3′-Deoxy-3′-[18F]Fluorothymidine PET

Abstract: This study demonstrated that lipoDox in combination with lipoVNB was more efficacious than clinically used regimen, lipoDox plus VNB, in the treatment of colon carcinoma and [F]FLT-PET is a promising approach in monitoring the treatment outcome at early stage.

Cited by 3 publications

References 29 publications

Liposomes as Multifunctional Nano-Carriers for Medicinal Natural Products

Liposomes as Multifunctional Nano-Carriers for Medicinal Natural Products

Tumor-Targeting Ability of Novel Anti-Prostate-Specific Membrane Antigen Antibodies

Fibronectin-targeted dual-acting micelles for combination therapy of metastatic breast cancer

Contact Info

Product

Resources

About